PACB — PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Nasdaq · Unknown · Unknown · CIK 1299130 ·
Last close
$1.26
Market Cap
$391.36M
52W High
$1.80
52W Low
$1.09
ADV30
6,327,293
Next earnings
2026-08-06
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solutions to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-read sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, the company provides Revio, Vega, and Sequel instruments which conduct, monitor, and analyze single-molecule biochemical reactions on SMRT cell microchips; short-read sequencing; and onso instrument. It serves academic and governmental research institutions, commercial testing and service laboratories, genome centers, public health labs, hospitals and clinical research institutes, contract research organizations, pharmaceutical companies, and agricultural companies. The company markets its products through a sales force and distribution partners in Australia, certain parts of Asia, Europe, the Middle East, Africa, Central America, and South America. It has a collaboration with DNAstack Inc. to provide federated dataset of HiFi whole genome sequencing data. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 37,178,000 12,841,000 -54,153,000 -8,275,000 782,365,000 56,274,000 779,999,000
Dec 2025 44,645,000 16,566,000 -41,197,000 -40,371,000 784,083,000 63,707,000 778,734,000
Sep 2025 38,441,000 15,901,000 -38,877,000 -38,000,000 803,158,000 56,467,000 767,068,000
Jun 2025 39,766,000 14,684,000 -44,853,000 -41,930,000 825,470,000 54,803,000 763,981,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-111,209,000
Investing CF
$115,448,000
Financing CF
$3,428,000
CapEx
$-9,417,000
Dividends Paid
Buybacks
EPS Diluted TTM
$-1.84
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,695,302,000
Inventory
$49,285,000
Receivables
$35,448,000
ST Investments
$215,799,000
EBIT TTM
$-539,104,000
Pretax Income TTM
$-546,058,000
Interest Exp TTM
$6,954,000
Analysts
6

Yahoo Snapshot (yfinance, live)

Total Revenue
$160,030,000
EBITDA
$-143,146,000
Free Cash Flow
$-48,237,124
Enterprise Value
$821,784,128
Total Cash
$275,961,984
Total Debt
$706,387,968
Shares Out
310,601,688
Trailing EPS
$-0.41
Book Value
$0.01
ROE
-273.6%
ROA
-12.0%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 160,005,000 -557,561,000 -546,376,000 784,083,000 778,734,000 -111,209,000
Dec 2024 154,014,000 -290,663,000 -309,851,000 1,260,447,000 753,853,000 -206,058,000
Dec 2023 200,521,000 -310,365,000 -306,735,000 1,746,013,000 1,044,709,000 -259,173,000
Dec 2022 128,304,000 -304,819,000 -314,248,000 1,767,086,000 1,204,182,000 -263,211,000

TTM Snapshot

Revenues TTM
$162,856,000
NetIncome TTM
$-188,023,000
OpCashFlow TTM
$0
Assets (Latest)
$1,260,447,000
Forward EPS
$-0.40

News headlines (Yahoo Finance, 1h cache)

PacBio SPRQ-Nx Chemistry Now Shipping Worldwide, Enabling Sub-$300 HiFi Genomes for Large Scale Projects and AI-Enhanced Sequencing
2026-05-26 13:05 · Yahoo
PacBio to Participate in the Jefferies Global Healthcare Conference
2026-05-21 20:05 · Yahoo
PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology
2026-05-20 15:15 · Yahoo
1 Stock Under $10 to Keep an Eye On and 2 We Avoid
2026-05-20 11:16 · Yahoo
Blank Bio Announces Seed Financing and Strategic Collaboration with PacBio to Advance RNA Foundation Models for Precision Oncology
2026-05-19 13:00 · Yahoo
Pacific Biosciences (PACB) Reports Q1 EPS
2026-05-13 06:20 · Yahoo
Why PacBio (PACB) Shares Are Getting Obliterated Today
2026-05-12 20:36 · Yahoo
PACB Q1 Deep Dive: Consumables Growth and Clinical Adoption Offset Instrument Weakness
2026-05-12 16:20 · Yahoo
3 Small-Cap Stocks We Find Risky
2026-05-12 15:08 · Yahoo
HiFi Solves Sub-fertility Consortium in Asia Pacific Reports First Major Study Using HiFi Long-Read Sequencing to Investigate Unexplained Subfertility and Recurrent Pregnancy Loss
2026-05-11 13:05 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.